Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors.
Fan Yang,Ran Meng,Da-Long Zhu +2 more
Reads0
Chats0
TLDR
Three aspects of SGLT2 inhibitors are summarized: the recent clinical evidence of their cardiovascular benefits, their mechanisms of action, and their safety.About:
This article is published in Chronic Diseases and Translational Medicine.The article was published on 2020-08-15 and is currently open access. It has received 4 citations till now. The article focuses on the topics: Kidney disease & Type 2 diabetes.read more
Citations
More filters
Journal ArticleDOI
Sodium-Glucose Cotransporter Type 2 Inhibitors and Cardiac Arrhythmias.
TL;DR: The antiarrhythmic mechanisms involved include reverse atrial and ventricular remodeling, amelioration of mitochondrial function, reduction of hypoglycemic episodes with their attendant arrhythmogenic effects, attenuated sympathetic nervous system activity, regulation of sodium and calcium homeostasis, and suppression of prolonged ventricular repolarization as discussed by the authors .
Journal ArticleDOI
Empagliflozin Alleviates Left Ventricle Hypertrophy in High-Fat-Fed Mice by Modulating Renin Angiotensin Pathway
Juliana C. Cotrin,Gabriel Santos Martins de Souza,Tamiris Ingrid Petito-da-Silva,Luiz E.M. Cardoso,Vanessa Souza-Mello,Sandra Barbosa-da-Silva +5 more
TL;DR: The results suggests that empagliflozin modulates the local RAS pathway towards alleviation of oxidative stress and ER stress in the LV, which may be a route to its effects on improved cardiac remodeling.
Journal ArticleDOI
Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis
F. B. Rivera,V. Tang,D. D. De Luna,Edgar V. Lerma,Krishnaswami Vijayaraghavan,Amir Kazory,Nilay Shah,Annabelle Santos Volgman +7 more
TL;DR: In this article , the authors explored potential sex differences in primary composite outcomes among patients with heart failure treated with SGLT-2is and found that the primary composite outcome was significantly lower in females compared with males.
Journal ArticleDOI
Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control
TL;DR: In this article , the authors focus on the possible effects of SGLT2 inhibitors on different body systems, including brain function, synaptic plasticity, acetylcholinesterase activity, and reduce amyloid plaque formation, as well as regulation of the mTOR pathway in the brain.
References
More filters
Journal ArticleDOI
Treatment strategies for hypertension in patients with type 1 diabetes.
Alexandra Katsimardou,Konstantinos Imprialos,Konstantinos Stavropoulos,Alexandros Sachinidis,Michalis Doumas,Vasilios G. Athyros +5 more
TL;DR: Although hypertension affects a substantial proportion of T1DM individuals, blood pressure control rates are disappointingly low and there is an urgent need for good quality data regarding proper antihypertensive treatment initiation, optimal BP targets and optimal antihyertensive treatment for better clinical outcomes.
Journal ArticleDOI
Diabetes without Manifest Cardiovascular Disease: A Novel Approach in Risk Stratification and Treatment Selection
Emile Andari,Samir Arnaout,Sami T. Azar,Elie Chammas,Selim Jambart,Mounzer Saleh,Rita Nemr,Antoine Sarkis +7 more
TL;DR: The panel formulated a stepwise algorithm by which patients with T2D undergo initial risk stratification into low, intermediate and high risk using the ASCVD calculator, and recommends using standard diabetes care in low risk patients and using SGLT2 inhibitors and GLP1 agonists with cardio protective effect in high risk individuals.